Safety Innovation RyMed focuses on innovative safety products for intravenous catheter management, presenting a recurring sales opportunity to hospitals seeking to reduce CR-BSIs and intraluminal thrombotic catheter occlusions.

Needleless Advantage Their InVision-Plus needleless connectors with Neutral Advantage Technology offer a differentiated value proposition that can be pitched as reducing infection risk and improving patient outcomes, appealing to infection control teams.

Chlorhexidine Silver Benefit The InVision-Plus CS product uses Chlorhexidine and Silver, a unique selling point for facilities prioritizing antimicrobial surfaces, potentially leading to higher adoption in competitive procurement cycles.

Growth and Reach With a small to mid-size employee base and revenue in the low to mid single-digit millions, RyMed presents an opportunity for strategic partnerships, distribution expansion, and co-marketing with larger hospital supplier networks.

Funding Leverage Recent funding of nearly $8 million suggests capacity for scale, accelerated R&D, and expanded channel investments, making it a favorable time for pilots, case studies, and regional deployments.